There are 14 papers on plasma Aβ42/Aβ40 ratio in aging research: 10 observational studies in people, 1 in animals, 2 reviews.
14 papers study it8 more mention it14 findings
See all 22 papers on plasma Aβ42/Aβ40 ratio
“higher AgeAccelHorvath and AgeAccelPheno were associated with lower amyloid beta (Aβ) 42 to Aβ40 (Aβ42:Aβ40) ratio”
- Humans10
- Animals1
- In silico1
Effects
2Late-onset epilepsy
no changein humans1
1 study
Late-onset epilepsy
no changein humans1
Plasma Aβ42/Aβ40 ratio was not clearly linked with late-onset epilepsy in humans (Isolated measurement).
HumansIsolated measurementplasman = 1,424
Cortical metabolism
no changein humans1
1 study
Cortical metabolism
no changein humans1
Plasma Aβ42/Aβ40 ratio was not clearly linked with cortical metabolism in humans (subjective memory complaints).
Humanssubjective memory complaintsbrainn = 261
Associations
12CSF Aβ42/Aβ40 ratio
upin mice1
1 study
CSF Aβ42/Aβ40 ratio
upin mice1
Plasma Aβ42/Aβ40 ratio is associated with CSF Aβ42/Aβ40 ratio in preclinical 5XFAD mice.
Animalsin preclinical 5XFAD mice
PSEN1 E280A mutation carrier status
mixedin humans1
1 study
PSEN1 E280A mutation carrier status
mixedin humans1
Plasma Aβ42/Aβ40 ratio predicts PSEN1 E280A mutation carrier status in humans (classification of carriers versus non-carriers by ROC curve) (AUC 0.99).
Humansclassification of carriers versus non-carriers by ROC curven = 164
PSEN1
mixedin humans1
1 study
PSEN1
mixedin humans1
PSEN1 is associated with plasma Aβ42/Aβ40 ratio in humans (carriers versus non-carriers; divergence age) (divergence before age 18 (Aβ42/Aβ40); 26.0 years (p-tau217); 26.1 years (GFAP); 27.9 years (BD-tau); 38.7 years (NfL)).
Humanscarriers versus non-carriers; divergence agen = 164
Progression from PET A- to A+
upin humans1
1 study
Progression from PET A- to A+
upin humans1
Plasma Aβ42/Aβ40 ratio predicts progression from PET A- to A+ in PET A- non-demented participants.
Humansin PET A- non-demented participants
PET Aβ burden
upin humans1
1 study
PET Aβ burden
upin humans1
Plasma Aβ42/Aβ40 ratio predicts PET Aβ burden in PET A- non-demented participants.
Humansin PET A- non-demented participants
Amyloid PET positivity
upin humans1
1 study
Amyloid PET positivity
upin humans1
Plasma Aβ42/Aβ40 ratio predicts amyloid PET positivity in humans (AUC 0.856).
Humansn = 474
Brain amyloid burden
upin humans1
1 study
Brain amyloid burden
upin humans1
Plasma Aβ42/Aβ40 ratio is associated with brain amyloid burden in humans.
Reviewplasma
AgeAccelPheno
downin humans1
1 study
AgeAccelPheno
downin humans1
AgeAccelPheno is associated with plasma Aβ42/Aβ40 ratio in humans (at baseline; same association for AgeAccelHorvath).
Humansat baseline; same association for AgeAccelHorvathfemales
AgeAccelHorvath
downin humans1
1 study
AgeAccelHorvath
downin humans1
AgeAccelHorvath is associated with plasma Aβ42/Aβ40 ratio in humans (at baseline; same association for AgeAccelPheno).
Humansat baseline; same association for AgeAccelPhenofemales
Cognitive function
mixedin humans1
1 study
Cognitive function
mixedin humans1
Plasma Aβ42/Aβ40 ratio is associated with cognitive function in humans (patients receiving hemodialysis; adjusted for age, sex and education levels).
Humanspatients receiving hemodialysis; adjusted for age, sex and education levels55% malesn = 311